Logo image of CVM

CEL-SCI CORP (CVM) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:CVM - US1508377066 - Common Stock

4.71 USD
+0.03 (+0.64%)
Last: 12/26/2025, 8:04:00 PM
4.71 USD
0 (0%)
After Hours: 12/26/2025, 8:04:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CVM. CVM was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of CVM have multiple concerns. CVM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CVM had negative earnings in the past year.
CVM had a negative operating cash flow in the past year.
In the past 5 years CVM always reported negative net income.
In the past 5 years CVM always reported negative operating cash flow.
CVM Yearly Net Income VS EBIT VS OCF VS FCFCVM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of CVM (-125.00%) is worse than 81.13% of its industry peers.
CVM has a Return On Equity of -361.85%. This is in the lower half of the industry: CVM underperforms 74.34% of its industry peers.
Industry RankSector Rank
ROA -125%
ROE -361.85%
ROIC N/A
ROA(3y)-76.3%
ROA(5y)-76.74%
ROE(3y)-142.28%
ROE(5y)-202.3%
ROIC(3y)N/A
ROIC(5y)N/A
CVM Yearly ROA, ROE, ROICCVM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CVM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVM Yearly Profit, Operating, Gross MarginsCVM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, CVM has more shares outstanding
The number of shares outstanding for CVM has been increased compared to 5 years ago.
The debt/assets ratio for CVM has been reduced compared to a year ago.
CVM Yearly Shares OutstandingCVM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
CVM Yearly Total Debt VS Total AssetsCVM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

CVM has an Altman-Z score of -39.23. This is a bad value and indicates that CVM is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -39.23, CVM is doing worse than 91.89% of the companies in the same industry.
CVM has a Debt/Equity ratio of 0.89. This is a neutral value indicating CVM is somewhat dependend on debt financing.
CVM has a worse Debt to Equity ratio (0.89) than 75.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Altman-Z -39.23
ROIC/WACCN/A
WACCN/A
CVM Yearly LT Debt VS Equity VS FCFCVM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.47 indicates that CVM may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.47, CVM is doing worse than 92.26% of the companies in the same industry.
A Quick Ratio of 0.37 indicates that CVM may have some problems paying its short term obligations.
With a Quick ratio value of 0.37, CVM is not doing good in the industry: 93.40% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.37
CVM Yearly Current Assets VS Current LiabilitesCVM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

CVM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.99%, which is quite impressive.
EPS 1Y (TTM)42.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.31% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.35%
EPS Next 2Y35.37%
EPS Next 3Y21.76%
EPS Next 5Y15.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CVM Yearly Revenue VS EstimatesCVM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2024 2027 2028 2029 100M 200M 300M 400M
CVM Yearly EPS VS EstimatesCVM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CVM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CVM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVM Price Earnings VS Forward Price EarningsCVM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CVM Per share dataCVM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

CVM's earnings are expected to grow with 21.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.37%
EPS Next 3Y21.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CVM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CEL-SCI CORP

NYSEARCA:CVM (12/26/2025, 8:04:00 PM)

After market: 4.71 0 (0%)

4.71

+0.03 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12
Earnings (Next)01-12 2026-01-12/amc
Inst Owners11.08%
Inst Owner Change63.3%
Ins Owners1.25%
Ins Owner Change3.86%
Market Cap37.77M
Revenue(TTM)N/A
Net Income(TTM)-25.42M
Analysts80
Price Target306 (6396.82%)
Short Float %5.16%
Short Ratio5.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.38
P/tB 5.48
EV/EBITDA N/A
EPS(TTM)-21.57
EYN/A
EPS(NY)-3.62
Fwd EYN/A
FCF(TTM)-2.16
FCFYN/A
OCF(TTM)-2.15
OCFYN/A
SpS0
BVpS0.88
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -125%
ROE -361.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-76.3%
ROA(5y)-76.74%
ROE(3y)-142.28%
ROE(5y)-202.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.47
Quick Ratio 0.37
Altman-Z -39.23
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)143.31%
Cap/Depr(5y)116.55%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.27%
EPS Next Y6.35%
EPS Next 2Y35.37%
EPS Next 3Y21.76%
EPS Next 5Y15.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year717.49%
EBIT Next 3Y181.37%
EBIT Next 5YN/A
FCF growth 1Y9.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.76%
OCF growth 3YN/A
OCF growth 5YN/A

CEL-SCI CORP / CVM FAQ

Can you provide the ChartMill fundamental rating for CEL-SCI CORP?

ChartMill assigns a fundamental rating of 1 / 10 to CVM.


Can you provide the valuation status for CEL-SCI CORP?

ChartMill assigns a valuation rating of 1 / 10 to CEL-SCI CORP (CVM). This can be considered as Overvalued.


Can you provide the profitability details for CEL-SCI CORP?

CEL-SCI CORP (CVM) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CEL-SCI CORP?

The Earnings per Share (EPS) of CEL-SCI CORP (CVM) is expected to grow by 6.35% in the next year.